|
AR039209A1
(es)
|
2002-04-03 |
2005-02-09 |
Novartis Ag |
Derivados de indolilmaleimida
|
|
CA2488798A1
(en)
*
|
2002-06-05 |
2003-12-18 |
Janssen Pharmaceutica N.V. |
Substituted pyrrolines as kinase inhibitors
|
|
RU2004135382A
(ru)
|
2002-06-05 |
2005-06-27 |
Янссен Фармацевтика Н.В. (Be) |
Замещенные пирролины в качестве ингибиторов киназы
|
|
GB0303319D0
(en)
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
|
WO2005025602A1
(en)
|
2003-09-16 |
2005-03-24 |
Garvan Institute Of Medical Research |
METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH
|
|
EP1682103A1
(en)
*
|
2003-10-27 |
2006-07-26 |
Novartis AG |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
|
AU2004289303A1
(en)
*
|
2003-11-10 |
2005-05-26 |
Synta Pharmaceuticals, Corp. |
Fused heterocyclic compounds
|
|
GB0401089D0
(en)
*
|
2004-01-19 |
2004-02-18 |
Novartis Ag |
Organic compounds
|
|
EP1709030B1
(en)
*
|
2004-01-19 |
2008-04-02 |
Novartis AG |
Indolylmaleimide derivatives
|
|
US20070232658A1
(en)
*
|
2004-04-08 |
2007-10-04 |
Jurgen Wagner |
Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
|
|
GB0410713D0
(en)
*
|
2004-05-13 |
2004-06-16 |
Novartis Ag |
Organic compounds
|
|
CA2589127C
(en)
|
2004-12-08 |
2013-02-05 |
Johannes Gutenberg-Universitat Mainz |
3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
|
|
GB0504203D0
(en)
*
|
2005-03-01 |
2005-04-06 |
Novartis Ag |
Organic compounds
|
|
GB0507918D0
(en)
|
2005-04-19 |
2005-05-25 |
Novartis Ag |
Organic compounds
|
|
WO2006117212A2
(en)
|
2005-05-04 |
2006-11-09 |
Develogen Aktiengesellschaft |
Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
US7781438B2
(en)
|
2005-07-11 |
2010-08-24 |
Novartis Ag |
Indolylmaleimide derivatives
|
|
PL2848258T3
(pl)
|
2005-10-26 |
2018-06-29 |
Novartis Ag |
Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
|
|
AU2006314444C1
(en)
|
2005-11-21 |
2018-01-04 |
Novartis Ag |
Neuroendocrine tumor treatment using mTOR inhibitors
|
|
GB0601744D0
(en)
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
GB0613162D0
(en)
*
|
2006-06-30 |
2006-08-09 |
Novartis Ag |
Organic compounds
|
|
US20100179175A1
(en)
*
|
2006-08-23 |
2010-07-15 |
Sivak Jeremy M |
Use of pkc inhibitors in ocular diseases
|
|
PE20081133A1
(es)
*
|
2006-10-20 |
2008-09-16 |
Novartis Ag |
Cristal acetato de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona
|
|
US20100075997A1
(en)
*
|
2006-12-07 |
2010-03-25 |
Alexander Korn |
Use of pkc inhibitors in transplantation
|
|
ES2410955T3
(es)
|
2006-12-19 |
2013-07-04 |
Novartis Ag |
Derivados de indolilmaleimida como inhibidores de la quinasa
|
|
JP2010520879A
(ja)
*
|
2007-03-09 |
2010-06-17 |
ノバルティス アーゲー |
３−（１ｈ−インドール−３−イル）−４−［２−（４−メチル−ピペラジン−１−イル）−キナゾリン−４−イル］−ピロール−２，５−ジオンの塩
|
|
CA2993565C
(en)
|
2007-05-29 |
2019-04-02 |
Novartis Ag |
New indications for anti-il-1-beta therapy
|
|
AU2008303540B2
(en)
*
|
2007-09-27 |
2012-04-26 |
Novartis Ag |
Drug monitoring assay
|
|
JP2011515068A
(ja)
|
2007-11-08 |
2011-05-19 |
ノバルティス アーゲー |
慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー
|
|
ATE535241T1
(de)
*
|
2007-12-05 |
2011-12-15 |
Univ Mainz Johannes Gutenberg |
Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
CA2767616A1
(en)
|
2009-07-09 |
2011-01-13 |
The Scripps Research Institute |
Gene expression profiles associated with chronic allograft nephropathy
|
|
RU2441000C2
(ru)
*
|
2009-11-27 |
2012-01-27 |
Общество с ограниченной ответственностью "Молекулярные Технологии" |
4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
|
|
EP2338486A1
(en)
|
2009-12-18 |
2011-06-29 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
|
|
EP2343291A1
(en)
|
2009-12-18 |
2011-07-13 |
Johannes Gutenberg-Universität Mainz |
3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
US8791100B2
(en)
|
2010-02-02 |
2014-07-29 |
Novartis Ag |
Aryl benzylamine compounds
|
|
CN102821759A
(zh)
|
2010-03-30 |
2012-12-12 |
诺华有限公司 |
用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2474541A1
(en)
|
2010-12-23 |
2012-07-11 |
Johannes- Gutenberg-Universität Mainz |
Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
CN102153605B
(zh)
*
|
2011-03-02 |
2014-02-19 |
福建省微生物研究所 |
一种咪唑立宾的提纯方法
|
|
UY34072A
(es)
|
2011-05-17 |
2013-01-03 |
Novartis Ag |
Derivados sustituidos de indol
|
|
PH12013502524A1
(en)
|
2011-06-27 |
2014-01-27 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
GB201111427D0
(en)
*
|
2011-07-05 |
2011-08-17 |
Amakem Nv |
Novel bisindolylmaleimides, pan-pkc inhibitors
|
|
CN103732596B
(zh)
|
2011-07-08 |
2016-06-01 |
诺华股份有限公司 |
吡咯并嘧啶衍生物
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US8846712B2
(en)
|
2011-09-12 |
2014-09-30 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2768813A1
(en)
|
2011-10-21 |
2014-08-27 |
Novartis AG |
Quinazoline derivatives as pi3k modulators
|
|
US20140348848A1
(en)
|
2011-12-02 |
2014-11-27 |
Dhananjay Kaul |
Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
|
|
CA2857302C
(en)
|
2011-12-15 |
2020-08-25 |
Novartis Ag |
Use of inhibitors of the activity or function of pi3k
|
|
PE20141598A1
(es)
|
2011-12-22 |
2014-11-14 |
Novartis Ag |
Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
|
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
|
WO2013167403A1
(en)
|
2012-05-09 |
2013-11-14 |
Sanofi |
Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
|
|
MX2015005737A
(es)
|
2012-11-07 |
2015-09-16 |
Novartis Ag |
Derivados de indol sustituido.
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
PL2925366T3
(pl)
|
2012-11-29 |
2018-08-31 |
Novartis Ag |
Kombinacje farmaceutyczne
|
|
ES2851208T3
(es)
|
2012-12-10 |
2021-09-03 |
Centogene Gmbh |
Uso de derivados de maleimida para prevenir y tratar el cáncer
|
|
EP2928466B1
(en)
*
|
2012-12-10 |
2020-10-28 |
Centogene GmbH |
Use of maleimide derivatives for preventing and treating leukemia
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
WO2014174478A1
(en)
|
2013-04-26 |
2014-10-30 |
Novartis Ag |
Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
|
|
CA2918938C
(en)
|
2013-09-22 |
2021-05-18 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
WO2015148868A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
MX2016013812A
(es)
|
2014-04-24 |
2017-03-09 |
Novartis Ag |
Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
|
|
EA201692140A1
(ru)
|
2014-04-24 |
2017-04-28 |
Новартис Аг |
Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
|
|
WO2015162461A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
US10443100B2
(en)
|
2014-05-22 |
2019-10-15 |
The Scripps Research Institute |
Gene expression profiles associated with sub-clinical kidney transplant rejection
|
|
US11104951B2
(en)
|
2014-05-22 |
2021-08-31 |
The Scripps Research Institute |
Molecular signatures for distinguishing liver transplant rejections or injuries
|
|
EP3825417A3
(en)
|
2014-05-22 |
2021-09-15 |
The Scripps Research Institute |
Tissue molecular signatures of kidney transplant rejections
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
RU2018108804A
(ru)
|
2015-08-14 |
2019-09-16 |
Новартис Аг |
Фармацевтические комбинации и их применение
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3187495A1
(en)
|
2015-12-30 |
2017-07-05 |
Johannes Gutenberg-Universität Mainz |
3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
|
WO2017134513A1
(fr)
|
2016-02-03 |
2017-08-10 |
Galderma Research & Development |
Nouveaux composes propynyl bi-aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
|
|
WO2018175302A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Polymer conjugates targeting c-src with reduced exposure
|
|
WO2018175340A1
(en)
|
2017-03-20 |
2018-09-27 |
Sienna Biopharmaceuticals, Inc. |
Reduced exposure conjugates modulating therapeutic targets
|
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
CN110551103B
(zh)
*
|
2018-05-30 |
2022-08-23 |
北京大学深圳研究生院 |
一种jak3选择性抑制剂
|
|
KR102503349B1
(ko)
|
2019-05-14 |
2023-02-23 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
MX2021014157A
(es)
|
2019-05-23 |
2022-01-04 |
Novartis Ag |
Formas cristalinas de un inhibidor btk.
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|